COR THERAPEUTICS kurz vor Break Even - 500 Beiträge pro Seite

[fry]

Cor soll ziemlich bald profitabel werden.

Quelle: http://netcog.com/ArticleView.asp?ArticleID=80967

, Fry.

[fry]

Eine weitere interesante Kleinigkeit zu Cor:

COR Übernahmekandidat durch Genentech/Roche.
Quelle: http://www.biospace.com/articles/biotechinsight111600.cfm

, Fry.

[fry]

Are business conditions good?
by: inflorida26 11/27/00 9:29 pm
Msg: 3747 of 3748

Decent move in CORR. But are business conditions really that great? If they were, wouldn`t the stock be in a long-term up-trend with insiders (those who know business conditions the best) buying into the price strength? Take a look at RYL. This stock has been moving up steadily for months. A few months ago an insider bought 3,000 shares at the $20 level and now the same insider just bought 5,000 shares at the $37 level right into price strength. Why? Obviously, the insiders feel the stock is going higher, business conditions must be robust. And who knows the business conditions better than the insiders? No one. For more info check out

http://insiderreview.com

, Fry.

[gholzbauer]

Kann von Bedeutung sein, muß nicht.


Tuesday December 12, 6:53 pm Eastern Time
Heart Drug Trials Halted
By TINA MOORE
Associated Press Writer
PHILADELPHIA (AP) -- Pharmaceutical giant SmithKline Beecham has halted clinical tests of a drug designed to fight strokes and heart attacks after a surprising number of patients died while taking it.

The 122 deaths are ``totally unexplained,`` said Dr. Eric Topol of the Cleveland Clinic, who led an independent investigation into Lotrafiban and reported safety concerns to SmithKline Beecham after a weekend review.

All 9,197 patients involved in the Phase III study of Lotrafiban were being notified to stop taking the drug.

``Getting this sort of recommendation, we felt the only responsible course was to close the trial,`` Rick Koenig, a SmithKline Beecham spokesman, said Tuesday.

Lotrafiban is part of a drug class intended to prevent blood clots that lead to heart attacks and strokes.

The patients were taking a combination of Lotrafiban and aspirin, Topol said. By comparison, only 92 people who were taking a placebo died in the double-blind study that has been ongoing for nearly two years.

The 122 patients, all of whom had heart or neurological conditions, did not die of heart attacks or strokes, Topol said. Bleeding was a problem during the tests, but was treatable with transfusions.

Researchers conduct Phase III studies to determine the effectiveness and monitor any side effects of new drugs. Topol said researchers had hoped Lotrafiban could provide a long-term treatment.

``We did monitor this trial more carefully than ever,`` Topol said.

Doctors are searching for an effective oral anti-clotting agent to treat people with recurring cardiovascular problems. Currently, hospitals give patients intravenous inhibitors to prevent clotting.

Topol has been involved in two previous studies of oral anti-clogging agents. When data from those trials was released in August 1999, Topol said, he recommended halting the Lotrafiban study.

But by then, he said, the tests were ``well under way.``

Two other trials of inhibitors in the same class -- Roxifiban and Chromofiban -- are ongoing. DuPont and COR Therapeutics are conducting those studies, Topol said.

Officials with Delaware-based DuPont and COR Therapeutics in San Francisco did not immediately return telephone calls Tuesday.

SmithKline Beecham, with U.S. headquarters in Philadelphia, markets more than 400 products, including the anti-depressant Paxil and the smoking cessation patch and gum known as Nicorette.

[puhvogel]

Die Meldung habe ich vorgestern schon gesehen. (BTW soviel wieder mal zum Thema 90 % Zulassungsquote, die vom Aktionär kolportiert wird, am liebsten mag den Ausdruck: "The drug is the latest of a new, once promising, class of heart drugs" )
Zur Erklärung: Integrilin ist ebenfalls ein Glycoprotein IIb/IIIa Blocker. Ich denke diese Familie ist aber zu sehr schon im klinischen Alltag etabliert.
Der Puhvogel

[DrDralle]

Ist das nicht toll wie sich COR wieder in Richtung Norden auf den Weg macht? Die News am 08.01.01 sind ja auch super

Gruß aus Stuttgart